Table 1.

Kaplan-Meier plotter analysis of clinicopathological factors for overall survival and Progression-free survivalin HCC patients.

Clinicopathological factors	Overall survival			Progression-free survival
	N	Hazard ratio	P-value	N	Hazard ratio	P-value
Sex
Female	118	2.53(1.37–4.67)	0.0023	120	2.11(1.24–3.59)	0.0047
Male	246	1.82(1.16–2.84)	0.0081	246	0.8(0.55–1.16)	0.2297
Stage
1	170	1.79(0.97–3.31)	0.0589	170	1.58(0.93–2.7)	0.0872
2	83	7.99(1.08–59.09)	0.0155	84	0.57(0.31–1.03)	0.0577
1+2	253	1.75(1.02–3.01)	0.0392	254	1.21(0.79–1.85)	0.3853
3	83	3.15(1.46–6.77)	0.002	83	1.62(0.94–2.78)	0.0768
2+3	166	2.88(1.6–5.2)	0.0002	167	1.22(0.82–1.82)	0.3209
4	4			5
3+4	87	2.47(1.32-4.61)	0.0035	88	1.67(0.97–2.86)	0.0599
Grade
1	55	3.25(1.25–8.47)	0.0109	55	1.56(0.65–3.74)	0.3133
2	174	2.52(1.38–4.62)	0.0019	175	1.56(0.97–2.5)	0.0618
3	118	1.82(0.93–3.56)	0.0751	119	0.69(0.38–1.23)	0.2081
4	12			12
AJCC_T
1	180	1.7(0.95–3.07)	0.0728	180	1.55(0.94–2.58)	0.0854
2	90	4.76(1.13–20.07)	0.0188	92	0.66(0.38–1.14)	0.13
3	78	2.55(1.18–5.51)	0.0136	78	1.48(0.83–2.65)	0.1858
4	13			13
Vascular invasion
micro	90	2.32(1.09–4.95)	0.0255	91	0.67(0.38–1.19)	0.168
macro	16			16
None	204	1.5(0.87–2.58)	0.1375	204	1.32(0.83–2.08)	0.2384
Race
White	181	1.66(1.03–2.66)	0.0355	183	1.48(0.97–2.26)	0.0685
Asian	155	2.74(1.41–5.33)	0.0019	155	1.82(0.97–3.39)	0.0566
Black or African American	17			17
Sorafenib treatment
Treated	29	4.18(0.9–19.36)	0.0484	30	1.99(0.88–4.48)	0.092
Alcohol consumption
yes	115	2.54(1.11–5.79)	0.0221	115	1.26(0.71–2.23)	0.4359
none	202	1.9(1.12–3.23)	0.0162	204	1.25(0.82–1.91)	0.3003
Virus hepatitis
Yes	150	2.13(1.08–4.18)	0.0255	152	0.67(0.4–1.12)	0.121
None	167	2.06(1.3–3.26)	0.0017	167	1.68(1.06–2.65)	0.0251

The meaning of the bold values is P-value < 0.05.